Teachers Retirement System of The State of Kentucky increased its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 1,528.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 186,189 shares of the biotechnology company's stock after acquiring an additional 174,752 shares during the period. Teachers Retirement System of The State of Kentucky owned about 0.13% of Biogen worth $42,056,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in BIIB. Align Financial LLC lifted its stake in shares of Biogen by 339.3% in the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 95 shares during the period. Bell Investment Advisors Inc purchased a new stake in Biogen in the 2nd quarter worth approximately $27,000. Provenance Wealth Advisors LLC bought a new position in shares of Biogen in the third quarter worth approximately $29,000. Canton Hathaway LLC purchased a new stake in shares of Biogen in the third quarter worth $31,000. Finally, Financial Freedom LLC purchased a new stake in shares of Biogen in the third quarter worth $34,000. 87.93% of the stock is owned by institutional investors.
Analyst Ratings Changes
BIIB has been the topic of several research analyst reports. HSBC boosted their price objective on Biogen from $165.00 to $175.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. Bank of America increased their target price on Biogen from $219.00 to $244.00 and gave the stock a "neutral" rating in a research report on Thursday, October 22nd. Weiss Ratings cut Biogen from a "hold (c)" rating to a "hold (c-)" rating in a report on Thursday, October 29th. Seaport Research Partners raised Biogen to an "outperform" rating in a report on Monday, October 12th. Finally, HC Wainwright upped their price target on Biogen from $251.00 to $270.00 and gave the stock a "buy" rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $254.41.
Read Our Latest Stock Analysis on Biogen
Biogen Stock Down 0.7%
Shares of BIIB stock opened at $251.65 on Tuesday. The company's fifty day simple moving average is $233.96 and its two-hundred day simple moving average is $205.42. Biogen Inc. has a 52 week low of $160.36 and a 52 week high of $261.00. The stock has a market cap of $37.20 billion, a P/E ratio of 107.54, a PEG ratio of 2.84 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39.
Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same quarter last year, the business posted $4.81 earnings per share. The business's quarterly revenue was up 10.6% compared to the same quarter last year. Analysts predict that Biogen Inc. will post 12.46 EPS for the current fiscal year.
Biogen Profile
(
Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.